RecruitingEarly Phase 1NCT07617740

IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)

An Exploratory Clinical Study on the Treatment of Active Refractory Systemic Lupus Erythematosus With IASO207 Injection

Sponsor

Peking University People's Hospital

Enrollment

18 participants

Start Date

May 25, 2026

Study Type

INTERVENTIONAL

Conditions

Refractory Systemic Lupus Erythematosus

Summary

This is a single-center, open-label, exploratory clinical study designed to evaluate the efficacy and safety of IASO207 Injection (in vivo CAR-T) in patients with active refractory systemic lupus erythematosus.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IASO207 Injection for people with refractory systemic lupus erythematosus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIASO207 Injection

IASO207 is a third-generation replication-deficient self-inactivating lentiviral vector that carries the gene encoding a second-generation anti-human CD19 chimeric antigen receptor (CD19 CAR) containing the 4-1BB co-stimulatory factor. IASO207 has been engineered through surface modification of the lentiviral envelope to enable it to selectively bind and transduce T cells within the body, thereby directly generating CD19 CAR-T cells in vivo.